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Abstract
Tumor necrosis factor-K (TNF-K) is one of the key cytokines elicited by host macrophages upon challenge with pathogenic
mycobacteria. Infection of human peripheral blood mononuclear cells or the murine macrophage cell line J774A-1 with Mycobacterium
avium induced activation of the mitogen-activated protein kinases (MAPKs) ERK1/2, p38 and c-Jun N-terminal kinase. U0126, an MEK-
specific inhibitor, abrogated M. avium-induced TNF-K secretion. Transfection of cells with dominant-negative MEK1 led to the
suppression of TNF-K release in M. avium-challenged macrophages. M. avium activated p38 MAPK and use of the p38 MAPK inhibitor,
SB203580, revealed that the p38 signaling pathway negatively regulates activation of ERK1/2 and release of TNF-K. Taken together, these
results provide evidence that M. avium-induced TNF-K release from macrophages depends on an interplay between the ERK1/2 and the
p38 MAPK signaling pathways. 5 2002 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Mycobacterium avium is an intracellular facultative bac-
terium that proliferates inside host macrophages [1]. It
causes severe pulmonary and disseminated disease in im-
munocompromised hosts, especially in individuals with
AIDS. The bacterium poses a particular threat in these
individuals in view of the fact that 40^50% of all patients
with M. avium infection are refractory to conventional
antibiotics and antimycobacterial drugs [2]. The success
of virulent mycobacteria as pathogens is attributed largely
to their ability to survive and multiply within macrophages
for extended periods of time. These phagosomes, unlike
those containing other bacteria, are arrested in their mat-
uration [3^6], lack lysosomal markers [7] and fail to be
acidi¢ed [8].
Designing e¡ective agents to combat M. avium necessi-
tates a thorough understanding of the host response to M.
avium infection. The production and balance of immuno-
modulatory cytokines and the activation of kinase cas-
cades and transcription factors are key elements of the
host cell response.
Infection of macrophages with M. avium induces the
production of tumor necrosis factor-K (TNF-K) [9], which
is one of the key cytokines responsible for mounting the
host response to infection. Macrophages harboring M.
avium undergo apoptosis [10] in a TNF-K-dependent man-
ner [11], which helps in the reduction of successive bacte-
rial growth and in the containment of infection. Under-
standing the mechanisms of TNF-K production should
further our understanding of the host cell defense against
M. avium and of the immunobiology of M. avium infec-
tion.
Mitogen-activated protein kinases (MAPKs) and their
upstream kinases activate a number of transcription fac-
tors and signal the induction of a variety of in£ammatory
genes in response to lipopolysaccharide [12], cytokines [13]
and mycobacterial lipoarabinomannan [14]. There are
three principal MAPK family members: (i) p46 and p54
c-Jun NH2-terminal kinase (JNK) or stress-activated pro-
tein kinase with multiple subisoforms, (ii) p38 MAPK with
K, L, Q, and N isoforms, and (iii) p42 and p44 extracellular
signal-regulated kinase (ERK1 and 2). MAPKs are acti-
vated by speci¢c upstream MAPK kinases (MKKs): (i)
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MKK4 and MKK7 activate JNK [15^17], (ii) MAPK/
ERK kinase 1/2 (MEK1/2) activates the ERKs [18] and
(iii) MKK3 and MKK6 activate p38 MAPK [19].
We asked whether MAPK signaling is involved in TNF-
K secretion by macrophages challenged with M. avium. We
made use of speci¢c inhibitors of ERK1/2 and p38 MAPK
as well as transfection with dominant-negative MEK1 to
delineate the MAPK signaling response elicited by M.
avium in murine macrophages. We demonstrate that
TNF-K secretion induced by M. avium in macrophages
occurs in a MEK1^ERK1/2-dependent manner. p38
MAPK is also activated by M. avium. We demonstrate
that p38 MAPK negatively regulates ERK1/2 activation
as well as TNF-K secretion in macrophages. We speculate
that one-way cross-talk between p38 MAPK and ERK1/2
MAPK is crucial in determining M. avium-mediated TNF-
K secretion from macrophages, and therefore in the overall
biological response leading to destruction or survival of
the bacterium within its host.
2. Materials and methods
2.1. Reagents
Antibodies against total MAPKs, phospho-speci¢c anti-
bodies and the Elk^glutathione S-transferase (GST) fusion
protein were purchased from Cell Signaling Technology,
Beverly, MA, USA. PD98059, SB203580, U0126, LY-
294002, wortmannin and protease inhibitors were ob-
tained from CN Biosciences (San Diego, CA, USA).
2.2. Isolation of human peripheral blood mononuclear cells
(PBMCs)
Blood was drawn from healthy adult volunteers into
heparinized (100 U ml31) syringes, layered on Ficoll-Hy-
paque (Amersham Biosciences, UK) and isolated by cen-
trifugation according to the manufacturers’ instructions.
Cells were incubated in dishes containing RPMI 1640 me-
dium supplemented with 25 mM HEPES, 2% penicillin
and streptomycin, 1% glutamine and 10% fetal bovine
serum for 1 h at 37‡C in a humidi¢ed CO2 (5%) incubator.
Dishes were washed to remove non-adherent cells. Cells
were v 90% adherent as determined by trypan blue dye
exclusion.
2.3. Culture of the murine macrophage-like cell line
J774A-1
The murine macrophage cell line J774A-1 was obtained
from the National Centre for Cell Science, Pune and main-
tained in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% heat-inactivated fetal bovine serum,
100 U ml31 penicillin and 100 Wg ml31 streptomycin in a
humidi¢ed atmosphere containing 5% CO2.
2.4. Growth of M. avium
M. avium (NCTC 8562, a virulent strain) was obtained
from the All India Institute of Medical Sciences, New
Delhi, India. M. avium was grown in Middlebrook 7H9
broth (Difco, Detroit, MI, USA) supplemented with oleic
acid^albumin^dextrose supplement and 0.04% Tween 80
until the mid-exponential phase, harvested, washed and
resuspended in a small volume of phosphate-bu¡ered sa-
line (PBS) containing 0.04% Tween 80. The suspension
was brie£y sonicated until no bacterial clumps could be
seen by microscopy. The preparation was diluted to a
concentration of 2U108 colony-forming units ml31 in
10% glycerol and stored in aliquots at 380‡C. Repeated
subculturing of M. avium in liquid medium was avoided in
order to prevent loss of virulence.
2.5. Plasmid constructs and transient transfections
Constructs CMV L-gal, CMV-MEK-wt and CMV
MEK2A (dn) were generously gifted by Dr. D.J. Temple-
ton, Case Western Reserve University, Cleveland, OH,
USA. Transient transfections were carried out using the
E¡ectene transfection reagent (Qiagen) according to the
manufacturer’s protocol. The L-gal reporter plasmid was
used to normalize transfection e⁄ciencies.
2.6. Infection and preparation of cell lysates
J774A-1 cells were cultured in 24-well tissue culture
plates at 4U105 cells per well and were infected with M.
avium at a multiplicity of infection (MOI) of 10. Cells were
lysed with 1% Triton X-100 and the lysate was diluted and
plated on 7H10 agar to quantitate the number of viable
intracellular bacteria. The incubation of J774-1 with M.
avium at a bacteria:macrophage ratio of 10:1 for 6 h led
to the infection of 50% of the cells. The viability of the
infected monolayers versus an uninfected control was
monitored by the trypan blue exclusion method. The via-
bility was v 95% in all of the experiments described. After
incubation with M. avium, the wells were washed with ice-
cold PBS to remove free bacteria. Cells were lysed with
lysis bu¡er (20 mM Tris^HCl pH 7.4, 1% (v/v) Nonidet P-
40, 10% (v/v) glycerol, 137 mM NaCl, 20 mM NaF, 1 mM
EDTA, 40 mM Na-L-glycerophosphate, 4 Wg ml31 each of
leupeptin, pepstatin and aprotinin, 1 mM Na3VO4, 1 mM
pefabloc, 1 mM benzamidine) on ice for 15 min. Cell
lysates were boiled for 5 min after the addition of
5ULaemmli sample bu¡er and subjected to Western blot-
ting. Where necessary, J774A-1 cells were ¢rst treated with
pharmacological inhibitors or vehicle (DMSO) alone, pri-
or to incubation with M. avium.
2.7. Western blotting
Whole cell lysates were separated on SDS^polyacryl-
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amide gels and the proteins transferred to PVDF mem-
branes. The blots were blocked with 5% non-fat dry
milk powder in Tris-bu¡ered saline (TBS) for 1 h at
room temperature, then incubated overnight at 4‡C with
primary antibodies diluted 1:1500 in TBST (TBS with 1%
(v/v) Tween 20) plus 5% bovine serum albumin. Following
three washes of 5 min each with TBST, the blots were
incubated with horseradish peroxidase-conjugated goat
anti-rabbit IgG secondary antibody (Cell Signaling Tech-
nology) in blocking bu¡er for 1 h at room temperature.
After three washes with TBST, the blots were developed
with BM chemiluminescence reagent (Roche Molecular
Biochemicals) and exposed to X-ray ¢lm (Kodak XAR5).
2.8. In vitro kinase assay
ERK1/2 MAPK activity was determined by a solid
phase kinase assay using GST^Elk1 (Cell Signaling Tech-
nology) as the substrate. After treatment, cells were lysed
in lysis bu¡er (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM Na-
pyrophosphate, 1 mM Na-L-glycerophosphate, 1 mM
Na3VO4) for 5 min on ice. After centrifugation at 10 000
rpm (Sorvall SS-34) for 5 min at 4‡C, supernatants were
incubated with immobilized phospho-ERK1/2 MAPK
monoclonal antibody (Cell Signaling Technology) accord-
ing to the manufacturer’s protocol. The beads were
washed twice with lysis bu¡er, followed by two washes
with kinase reaction bu¡er (25 mM Tris^HCl pH 7.5, 10
mM MgCl2, 5 mM Na-L-glycerophosphate, 2 mM dithio-
threitol, 100 WM Na3VO4). The beads were then incubated
with 2 Wg GST^Elk1 fusion protein in 20 Wl kinase reac-
tion bu¡er containing 200 WM ATP. After incubation for
30 min at 30‡C, the reaction was terminated by the addi-
tion of 5ULaemmli sample bu¡er. Phosphorylated pro-
teins were resolved on an SDS^polyacrylamide (10%) gel
followed by Western blotting. Blots were probed with anti-
phospho-Elk antibody and visualized using a chemilumi-
nescence detection kit.
2.9. TNF-K measurement in culture supernatants
J774A-1 cells were either left untreated or were treated
with vehicle (DMSO), U0126, PD98059 or SB203580 fol-
lowed by incubation with M. avium. The conditioned me-
dium was removed and assayed for TNF-K by enzyme-
linked immunosorbent assay using the murine BIOTRAK
TNF-K assay kit (Amersham Biosciences, UK) according
to the manufacturer’s protocol. The limit of detection was
10 pg TNF-K ml31.
Fig. 1. ERK, p38 and JNK MAPKs are activated in M. avium-infected macrophages. Human PBMCs or J774A-1 macrophages were left untreated
(lanes C) or treated at di¡erent ratios (2, 5 and 10) of bacteria:host cell for 45 min (A, C and E). J774A-1 cells were treated with M. avium (bacteria:
host cell, 10:1) for various lengths of time (indicated in minutes in B, D and F). Cellular extracts were analyzed by Western blotting for the presence
of phospho-MAPKs. Each of the blots was also probed with antibodies against total ERK1/2, p38 and JNK MAPK antibodies to ensure that these
were present in equal amounts in all lanes. The graphs to the right of B, D and F show the corresponding densitometric analyses of the blots probed
with anti-phospho-MAPK antibodies (data from three independent experiments ; bars represent the meanU S.D.).
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2.10. Statistical analysis
Data obtained from three independent experiments are
represented as meanUS.D.; comparison was by the Stu-
dent’s t-test. Di¡erences were considered signi¢cant when
P6 0.05.
3. Results
3.1. M. avium infection leads to the activation of ERK,
JNK and p38 MAPKs in macrophages
The phosphorylation of the three members of the
MAPK family was considered to be an index of MAPK
activation. Human PBMCs or the murine J774A-1 (mac-
rophage-like) cell line were challenged with M. avium at
di¡erent ratios of bacteria to host cell. Phosphorylation of
all three members of the MAPK family occurred in both
cell types and increased with increasing ratios of bacteria
to host cell (Fig. 1A, C and E). Time-dependent phos-
phorylation of all three members of the MAPK family
was observed on challenging J774A-1 cells with M. avium.
M. avium stimulated phosphorylation of the MAPKs
within 30^60 min of exposure (Fig. 1B, D and F). The
activation time courses of all three MAPKs were simi-
lar.
Fig. 2. E¡ect of pharmacological inhibitors of ERK and p38 MAPK on M. avium-induced MAPK activation. J774A-1 macrophages were treated with
just medium (control) or vehicle (DMSO control) or with the MAPK-speci¢c inhibitors PD98059, U0126 and SB203580, or with the non-speci¢c inhibi-
tors LY294002 and wortmannin, for 30 min prior to incubation (45 min) with M. avium. Cells were lysed and subjected to Western blot analysis with
anti-phospho-ERK1/2 (A and C) and anti-p38 MAPK (B). Each of the blots was also probed with antibodies against total ERK1/2 (A and C), and
p38 (B) MAPK antibodies to ensure that these were present in equal amounts in all lanes. A densitometric analysis of the blots of panel C probed with
anti-phospho-ERK1/2 antibodies is shown (data from three independent experiments ; bars represent the meanU S.D.).
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3.2. Speci¢c inhibitors block M. avium-stimulated MAPK
activation
The pharmacological inhibitors U0126 [20] and
PD98059 [21,22] speci¢cally inhibit MEK without inhibit-
ing other MAPK pathways. Macrophages were treated
with vehicle only or with these inhibitors for 30 min prior
to challenge with M. avium. Extracts were then analyzed
by Western blotting for phosphorylated ERK1/2. U0126
and PD98059 both blocked ERK1/2 phosphorylation
mediated by M. avium (Fig. 2A), while exerting no e¡ect
on p38 MAPK. We also examined the e¡ect of SB203580,
which speci¢cally inhibits p38 MAPK [23]. Pretreatment
of cells with SB203580 (10 WM) caused complete inhibition
of the phosphorylation of p38 MAPK (Fig. 2B). On the
other hand, treatment with LY294002 or wortmannin,
which do not inhibit MAPKs, had no e¡ect on M.
avium-induced MAPK activation.
SB203580 treatment led to a signi¢cant increase in the
phosphorylation of ERK1/2 MAPK in a dose-dependent
manner (Fig. 2C) as determined by immunoblot analysis
with antibodies speci¢c to phospho-ERK1/2 and densito-
metric scanning of the blots. Maximum activation of
ERK1/2 was observed at 10 WM SB203580, which showed
maximum inhibition of p38 MAPK.
3.3. M. avium activates ERK1/2 in a MEK1-dependent
pathway
Phosphorylation of ERK by MEK activates this kinase,
resulting in the phosphorylation and activation of the
transcription factor Elk1. We determined ERK activity
in J774A-1 cells incubated with M. avium using an in vitro
kinase assay. Cell extracts were prepared and subjected to
immunoprecipitation using an immobilized antibody di-
rected against phosphorylated ERK (residues Thr-202
and Tyr-204). The immunoprecipitated proteins were sub-
jected to an in vitro kinase assay using puri¢ed GST^Elk1
fusion protein as a substrate. Anti-GST antibody was used
to con¢rm that equal amounts of Elk1 were present in all
reactions. M. avium-mediated ERK activation led to the
phosphorylation of Elk1. This could be inhibited by the
pretreatment of cells with the MEK1 inhibitor U0126 in a
dose-dependent manner (Fig. 3A). Further evidence that
M. avium mediates ERK1/2 activation in a MEK1-depen-
dent pathway was provided by the observation that the
transfection of cells with MEK2A (dn) led to the abroga-
tion of ERK1/2 kinase activity (Fig. 3B).
3.4. M. avium stimulates release of TNF-K from J774A-1
macrophages in a ERK1/2-dependent pathway
M. avium stimulated the secretion of TNF-K (Fig. 4).
Fig. 3. Dominant-negative MEK1 abrogates M. avium-stimulated activa-
tion of ERK1/2. A: J774A-1 cells were treated with DMSO or U0126
for 30 min prior to incubation with M. avium. Cellular extracts were
prepared and subjected to immunoprecipitation with immobilized anti-
phospho-ERK1/2. Immunoprecipitates were added to an in vitro kinase
assay using puri¢ed GST^Elk1 as substrate, and analyzed by Western
blotting using anti-phospho-Elk1 antibody. Probing with anti-GST anti-
body veri¢ed equal loading in all lanes. The data shown are representa-
tive of three independent determinations. B: J774A-1 cells were trans-
fected with wild-type (wt-MEK) or dominant-negative (dn-MEK)
MEK1 prior to incubation with M. avium as described above. The im-
munoprecipitation/kinase assay using GST^Elk1 as substrate was per-
formed as described for panel A. Data shown are representative of three
independent experiments.
Fig. 4. M. avium stimulates TNF-K secretion in J774A-1 macrophages
in a MAPK-dependent pathway. Monolayers of J774A-1 macrophages
were cultured alone or with M. avium, with and without a 30-min pre-
treatment with the MEK1 inhibitor U0126 and/or the p38 MAPK in-
hibitor SB203580. The release of TNF-K was measured in the condi-
tioned medium after 6 h. Data are from three independent experiments;
bars represent the meanUS.D.
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Maximal secretion occurred after 6^8 h of incubation of
M. avium with J774A-1 macrophages at an MOI of 10
(data not shown). All subsequent experiments were per-
formed by incubation of J774A-1 macrophages for 6 h
with M. avium. In order to understand whether the
MAPK pathway regulates M. avium-mediated TNF-K re-
lease, we studied TNF-K release both in the absence and in
the presence of MAPK inhibitors.
We observed that inhibition of ERK1/2 MAPK by
U0126 (10 WM) led to a four-fold reduction in TNF-K
release (Fig. 4). On the other hand, treatment of cells
with the p38 MAPK inhibitor SB203580 led to an increase
in TNF-K release which could be o¡set by treatment of
cells with U0126 in combination with SB203580. Inhibi-
tion of TNF-K release mediated by the combination of
SB203580 and M. avium supports the proposal that
TNF-K release occurs in an ERK1/2-dependent manner.
4. Discussion
In the present study we provide evidence that synthesis
of TNF-K occurs as an early response to the challenge of
the murine macrophage-like cell line J774A-1 by M.
avium. We asked whether the MAPK signaling pathways
were involved in TNF-K synthesis by M. avium-infected
macrophages.
J774A-1 is a mouse cell line that possesses character-
istics typical of macrophages [24]. In recent years,
J774A-1 cells have been used extensively in the study of
the infection and intracellular survival/apoptosis of many
bacteria including mycobacteria [6,7,25,26]. J774A-1 was
therefore chosen as a model to understand M. avium-in-
duced activation of all three MAPK pathways. In addi-
tion, MAPK activation by M. avium was also tested in
human PBMCs. Activation of all three MAPKs occurred
in both cell types and was dependent upon the ratio of
bacteria to host cell. Further studies were carried out in
J774A-1 cells. Activation of the ERK1/2 MAPKs by M.
avium was inhibited by the MEK-speci¢c inhibitors
PD98059 and U0126, suggesting that the MEK1^ERK1/
2 pathway was stimulated by M. avium challenge. This
argument was strengthened by the observation that the
transfection of cells with MEK2A (dn) abrogated phos-
phorylation of ERK1/2 by M. avium. In addition, it was
observed in in vitro kinase assays that M. avium stimu-
lated Elk1 phosphorylation which could be abrogated
when cells were transfected with MEK2A (dn), suggesting
that M. avium stimulates the MEK1^ERK1/2 pathway in
murine macrophages.
M. avium activation of the p38 MAPK pathway was
inhibited by the p38-speci¢c pyridinyl imidazole com-
pound SB203580 [23], a cell-permeable inhibitor that binds
to the ATP-binding site of p38. In addition, SB203580
treatment of cells led to an enhanced activation of
ERK1/2 phosphorylation mediated by M. avium, suggest-
ing that the p38 MAPK pathway negatively regulates the
activation of ERK1/2.
TNF-K is thought to mediate pathologic in£ammatory
reactions [27] and protective responses to bacterial infec-
tions [28]. It is principally expressed in macrophages [29].
We have presented evidence that stimulation of the
MAPK pathway by M. avium is causally linked to TNF-
K secretion in J774-1 macrophages. The ERK1/2 MAPK
activation correlated directly with induction of TNF-K
secretion elicited by M. avium. The treatment of cells
with SB203580 activated the M. avium-stimulated secre-
tion of TNF-K. Activation of TNF-K release by
SB203580 could be reversed when cells were treated with
a combination of SB203580 and U0126. Taken together,
these data suggest that M. avium-mediated ERK1/2 acti-
vation is directly related to the stimulation of TNF-K syn-
thesis in murine macrophages, while p38 MAPK inhibits
ERK1/2 activation and thereby negatively regulates TNF-
K synthesis. The regulation of TNF-K release is unlikely to
follow a common pathway, but is more likely to be strain-,
cell type- and stimulus-speci¢c. Several recent reports sup-
port this proposal. While SB203580 reduces TNF-K syn-
thesis induced by lipopolysaccharide in macrophages [23],
it enhances TNF-K secretion from stimulated mast cells
[30]. p38 MAPK has been reported to inhibit low density
lipoprotein receptor expression through inhibition of the
ERK1/2 signaling pathway in HepG2 cells [31]. In the
present study, the e¡ect we saw of SB203580 on M.
avium-stimulated TNF-K release argues in favor of the
view that p38 MAPK negatively regulates ERK1/2 signal-
ing and TNF-K release stimulated by M. avium in murine
Fig. 5. Model of the regulation of TNF-K secretion through ERK1/2
and p38 MAPK signaling by M. avium in J774A-1 macrophages.
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macrophages. It is worth noting in this context that p38
MAPK inhibition resulted in increased TNF-K release in
murine models of M. tuberculosis infection [32]. This was
accompanied by severely reduced bacterial clearance. A
recent report by Chan et al. [14] showed that SB203580
does not block, but rather enhances lipoarabinomannan-
induced nitrite production in macrophages. The present
study demonstrates that p38 MAPK-mediated inhibition
of ERK1/2 is a one-way cross-talk between the two path-
ways, since the ERK1/2 MAPK does not regulate p38
MAPK.
In conclusion, we have demonstrated that M. avium
stimulates TNF-K secretion from macrophages in a
MEK1^ERK1/2-dependent manner (Fig. 5). While this
work was in progress, Reiling et al. [33] demonstrated
that M. avium-induced TNF-K secretion from peripheral
blood monocytes is regulated by MAPKs. Tse et al. [34]
have also shown that both the avirulent and virulent mor-
photypes of M. avium activate all three MAPKs in macro-
phages. These results support our ¢ndings. Tse et al. ob-
served that only the growth of the avirulent morphotype
was controlled by the activation of ERK1/2 and the pro-
duction of TNF-K. We have demonstrated for the ¢rst
time that a one-way cross-talk between p38 and ERK1/2
MAPKs is responsible for the p38 MAPK-mediated in-
hibition of ERK1/2, and therefore of TNF-K secre-
tion. Since M. avium stimulates both ERK1/2 and p38
MAPK, the interplay between these signaling cascades
and their dynamic balance may be critical for determining
whether TNF-K secretion upon the challenge of J774A-1
macrophages with M. avium leads to macrophage apopto-
sis and containment of the bacterial infection, or whether
suppression of TNF-K secretion mediated by the p38
MAPK pathway leads to prolonged survival of M. avium
within macrophages. This distinct usage of MAPK path-
ways needs to be taken into careful consideration when
de¢ning targets along the MAPK pathway for therapeutic
intervention of mycobacterial infection. Detailed studies
into the inhibition of individual MAPK pathways and
the survival of avirulent and virulent morphotypes are
also warranted.
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